This is a Phase 1, single-centre, randomized, double-blind, placebo-controlled, MAD study in
healthy male and female adult subjects.
The study will include up to 48 subjects (12 subjects per cohort) who will be randomized 9:3
to active drug or placebo. Each cohort will receive AZD4041 or placebo in a MAD study.
A sequential cohort MAD design will be employed to assure that higher doses are administered
to healthy subjects only after lower doses have demonstrated an acceptable safety profile.
The total study duration will be up to 59 days (including Screening) per subject.